• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Abbott Alinity h-series hematology system

FDA clears Abbott Alinity h-series hematology system

August 7, 2023 By Sean Whooley

Abbott Alinity h-series hematology system
The Alinity h-series hematology system. [Image courtesy of Abbott]
Abbott (NYSE: ABT) announced today that the FDA cleared its advanced Alinity h-series hematology system.

FDA clearance enables laboratories to run complete blood counts (CBCs) as part of Abbott’s Alinity family of diagnostic products. CBCs, among the most ordered tests in healthcare, help to screen for a variety of disorders. That includes infections, anemia, diseases of the immune system and blood cancers.

The Alinity h-series includes Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. Abbott said Alinity hq’s key differentiator is the leveraging of advanced MAPSS technology. MAPSS uses light scattering to distinguish cellular features and better identify various blood cells.

Abbott says that bringing the Alinity h-series to market enables it to offer one of the broadest laboratory diagnostic systems available. It provides a wide array of tests that doctors can use to quickly and effectively care for their patients. Laboratories can seamlessly integrate the hematology system into their existing core lab operations, too, saving time and resources.

More features of the Abbott Alinity h-series

Alinity h-series processes up to 119 CBC results per hour and requires less floor space in the laboratory. It loads samples from the front and from a laboratory automation system and ensures urgent samples receive priority without compromising capacity or workflow.

Additionally, the system offers hands-off maintenance so labs can schedule automated daily and weekly cleanings. It integrates the slide maker with the analyzer to reduce manual intervention and provides customizable reports and rules. Alinity h-series also centralizes results and control functions at a single point.

The Alinity family now includes the Alinity h-series, Alinity ci, Alinity m, Alinity s and the point-of-care i-STAT Alinity.

“U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic,” said Louis Morrone, EVP for Abbott’s core diagnostics business. “The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”

Filed Under: Blood Management, Diagnostics, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Lab Instruments & Supplies, Regulatory/Compliance Tagged With: Abbott, FDA

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy